research
HIV-1 Vaccine Development: studies in Macaque models
- Publication date
- 5 November 1997
- Publisher
- Since its discovery about 15 years ago, human immunodeficiency virus type 1
(HtV-1) continues·to spread at an alarming rate. It is estimated that by the year 2000
between 30 and 40 million people will be infected with this virus worldwide'. Of these,
about 90 % live in developing countries. To date, more than six million people have
already developed to the fatal acquired immunodeficiency syndrome (AIDS). Despite
numerous research efforts no vaccination or generally accessible therapeutic approach
has become available yet.
In 1981, the first case of AIDS was recognized'. Epidemiologic studies implicated
an infectious agent and in 1983, the isolation of a previously unknown human retrovirus
called lymphadenopathy-associated virus (LA V) from an AIDS patient was reported by
Barre-Sinoussi et al.'. In 1984, Gallo et aI' and Levy et a/s also reported the isolation of
retroviruses from AIDS patients which they called human T-Iymphotropic virus type III
(HTLV-III) and AIDS-associated retrovirus (ARV), respectively. Soon thereafter, these
retroviruses were recognized as members of the Lentivirinae, a subfamily of the
Retroviridae, and were indeed identified as the etiological agents of AIDS. In 1986,
these retroviruses were named human immunodeficiency virus (HIV). Today, two types
of HIV are recognized, HIV-1 and HIV-2. Of these, HIV-1 is the primary etiologic agent
of the current AIDS pandemic. The search for an HIV-1 counterpart in other primate
species led to the identification of several simian immunodeficiency viruses (SIV), which
may cause AIDS like syndromes in monkeys'. Currently, macaque lentivirus infections
are considered the most appropriate animal models to study HIV pathogenesis and
possible intervention strategies.
In the following section, a concise overview is given of the biology of primate
lentiviruses, including the host immune response and correlates of immune-mediated
protection. Aspects important for vaccine development are highlighted.